Andra AP fonden Has $39.24 Million Stock Holdings in Zoetis Inc. $ZTS

Andra AP fonden boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 136.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 268,200 shares of the company’s stock after purchasing an additional 155,000 shares during the period. Andra AP fonden owned 0.06% of Zoetis worth $39,243,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ZTS. Savvy Advisors Inc. boosted its holdings in Zoetis by 54.0% in the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after purchasing an additional 1,114 shares in the last quarter. CIBC Asset Management Inc boosted its stake in shares of Zoetis by 4.3% during the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after acquiring an additional 10,434 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its holdings in shares of Zoetis by 6.5% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after acquiring an additional 18,040 shares during the last quarter. Ninety One UK Ltd raised its stake in shares of Zoetis by 19.6% in the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after acquiring an additional 183,686 shares in the last quarter. Finally, Quilter Plc lifted its holdings in Zoetis by 10.2% in the 3rd quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after purchasing an additional 40,615 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Up 0.5%

Shares of ZTS stock opened at $129.65 on Friday. The firm has a fifty day moving average of $125.88 and a 200-day moving average of $134.28. The stock has a market cap of $54.73 billion, a price-to-earnings ratio of 21.54, a P/E/G ratio of 1.97 and a beta of 0.96. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.6%. Zoetis’s payout ratio is currently 35.22%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ZTS shares. Piper Sandler reissued a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Stifel Nicolaus cut their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. Finally, JPMorgan Chase & Co. lowered their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Hold” and an average price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.